Search clinical trials for: IBI305

Total 360 results

Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Advanced Cervical Cancer

China
Harbin Medical University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Tongji Hospital
Wuhan University; Henan Cancer Hospital; Qilu Hospital of Shandong University; Hubei... and other collaborators

Recruiting

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA)

Ovarian Clear Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Acral Melanoma That Has Been Removed by Surgery

China
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Hepatocellular Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Shenzhen People's Hospital

Recruiting

Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

Lipid Metabolism Disorders | Familial Hypercholesterolemia - Homozygous | Proprotein Convertase Subtilisin/Kexin 9

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Safety and Tolerance Study of IBI355 in Health Volunteers

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in HeFH Patients

Heterozygous Familial Hypercholesterolemia

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization (STOP)

Precancerous Conditions | Oral Cavity Cancer | Mouth Neoplasm

China
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

CLDN18.2 Positive Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

Advanced/Metastatic Solid Malignancies

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

Hypercholesterolemia

China
Hunan Province Tumor Hospital
Xiangya Hospital of Central South University

Recruiting

The Efficacy and Safety of IBI363 in Solid Tumors. (Promise)

Advanced Solid Tumor

China
Wuhan Union Hospital, China

Recruiting

Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Beijing Tsinghua Chang Gung Hospital

Unknown

Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis

Hepatocellular Carcinoma | Portal Vein Tumor Thrombosis

China
Fujian Haixi Pharmaceuticals Co., Ltd.

Recruiting

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

COVID-19

China
Shandong Cancer Hospital and Institute

Not yet recruiting

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI306 in Participants With Hypercholesterolemia

Hypercholesterolemia

China
Mian XI

Recruiting

Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) (ISBRT01)

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Overweight/Obesity

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

China
Sichuan Cancer Hospital and Research Institute
Innovent Biologics, Inc.

Unknown

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-small-cell Lung Cancer
Taizhou Hospital

Unknown

CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients (CARTAI)

Thoracic Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

Healthy Male Subjects

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Metastatic Undifferentiated Pleomorphic Sarcoma | Recurrent Undifferentiated Pleomorphic Sarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Unresectable Undifferentiated Pleomorphic Sarcoma

United States
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumor

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

Thyroid Eye Disease, TED

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI363 in Subjects With Advanced Melanoma

Melanoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study of IBI323 in Patients With Advanced Malignancies

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Novartis Pharmaceuticals

Active, not recruiting

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Advanced Malignancies That Harbor IDHR132 Mutations

Belgium, Germany, Spain, Canada, Australia, United States, Netherlands, Singapore
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

Renal Impairment

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study of IBI318 in Participants With Advanced Malignancies

Advanced Malignancy

China
University of Texas Southwestern Medical Center

Withdrawn

Phase 2 Study of IDH305 in Low Grade Gliomas

Glioma
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Solid Tumor

Australia

Search clinical trials for: IBI305

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations